Cardiac sympathetic innervation

Ongoing clinical trials and approved products targeting Cardiac sympathetic innervation, in radioligand therapy and PET/SPECT imaging. Data as of 26 October 2026.

0ongoing therapy trials

4ongoing imaging trials

0approved products

Target note

Full name: Sympathetic innervation of the myocardium
Nature: Uptake by the norepinephrine transporter of cardiac sympathetic nerve terminals.
Normal expression: Myocardium, liver, salivary glands.
Value: Prognosis of heart failure and arrhythmic risk; helps diagnose synucleinopathies (cardiac denervation).
Approaches: SPECT: [123I]MIBG (heart-to-mediastinum ratio); PET: [18F]LMI1195, [11C]hydroxyephedrine.
Indications explored: Heart failure, ventricular arrhythmias, Parkinson's disease and dementia with Lewy bodies.
Points of caution: Drug interactions; standardisation of the heart-to-mediastinum ratio across cameras.

Ongoing imaging trials · 4Open in the radar →

Trial	Phase	Status	Sponsor	Countries
MIBG and analogues (innervation, neural crest)NCT06965621 · Ischemic heart disease	Phase 2	Recruiting	Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)	1
MIBG and analogues (innervation, neural crest)NCT04535193 · Atherosclerosis and vessels	Phase 2	Active, not recruiting	Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)	1
MIBG and analogues (innervation, neural crest)2024-513310-36-01 · Cardiac amyloidosis	Phase 1	Not yet recruiting	Universitair Medisch Centrum Groningen	1
AMEND · MIBG and analogues (innervation, neural crest)NCT02116140 · Heart failure and cardiomyopathies	No phase	Active, not recruiting	Ottawa Heart Institute Research Corporation	1

Cite this page

Cardiac sympathetic innervation. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 26 October 2026. https://theranosticatlas.com/target/cardiac-sympathetic-innervation/ (accessed [date]).

A monitoring tool with no regulatory value: check every item at its source.